<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="772">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698993</url>
  </required_header>
  <id_info>
    <org_study_id>Dräger Antigen Test SARS-CoV-2</org_study_id>
    <nct_id>NCT04698993</nct_id>
  </id_info>
  <brief_title>Dräger COVID-19 Antigen Test Clinical Performance Study</brief_title>
  <official_title>Dräger Antigen Test SARS-CoV-2 Clinical Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2&#xD;
      detection in clinical nasal specimens. Real-time polymerase chain reaction (RT-PCR) on&#xD;
      specimens collected by pharyngeal swabs serves as a reference method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Dräger Antigen Test SARS-CoV-2 is a rapid lateral flow immunoassay for the qualitative&#xD;
      detection of SARS-CoV-2 nucleoprotein directly from less invasive nasal swabs, to be&#xD;
      performed at the point of care. The test kit contains all components required to carry out a&#xD;
      test detecting SARS-CoV-2 nucleoprotein.&#xD;
&#xD;
      The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2&#xD;
      detection in clinical nasal specimens. Real-time polymerase chain reaction (RT-PCR) on&#xD;
      specimens collected by pharyngeal swabs serves as a reference method.&#xD;
&#xD;
      For this study, the goal is to compare at least 100 positive and 200 negative Dräger tests of&#xD;
      symptomatic participants with symptom onset 0-7 days ago to the corresponding PCR data.&#xD;
      Another goal is to test at least 100 asymptomatic participants with the Dräger Antigen Test&#xD;
      SARS-CoV-2.&#xD;
&#xD;
      Specimens are collected from patients showing COVID-19 symptoms as well as asymptomatic&#xD;
      participants. Participants are recruited across all genders and eligible age groups. Study&#xD;
      staff records participants' information such as symptoms and time since symptom onset. For&#xD;
      each study participant, the Dräger test specimen is collected first, then the specimen for&#xD;
      RT-PCR. The Dräger test result is read after 15 min to 20 min.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Sensitivity of antigen test compared with reference standard PCR test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Specificity of antigen test compared with reference standard PCR test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ease of use</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Demonstrate ease of use for patient and operator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between Dräger test result and specimen viral load</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Correlation between the Dräger test result and the viral load within the specimen (theoretical, relative and/or absolute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between Dräger test result and time since symptom onset</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Correlation between the Dräger test result and time since symptom onset (in symptomatic participants)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1650</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Collection of specimens from symptomatic COVID-19 positive participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dräger Antigen Test SARS-CoV-2</intervention_name>
    <description>Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_label>Symptomatic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must require SARS-CoV-2 testing for the following reasons:&#xD;
&#xD;
               -  COVID-19 symptoms (Fever, cough and/or sore throat, fatigue/ general feeling of&#xD;
                  weakness, loss of sense of smell and/or taste, shortness of breath, muscle&#xD;
                  stiffness/ body aches, head cold/ running nose, etc.) on the day of testing, or&#xD;
&#xD;
               -  Known or suspected exposure to SARS-CoV-2 (contact persons etc.), or&#xD;
&#xD;
               -  Member of a group of high risk of exposure such as healthcare workers etc., or&#xD;
&#xD;
               -  Require screening for any other reason, e.g. doctor's orders, hygiene directive&#xD;
                  etc.&#xD;
&#xD;
          -  Participant must be of legal age and must be able to understand the procedure and&#xD;
             letter of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years old are excluded from the study.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients are excluded from the study.&#xD;
&#xD;
          -  Patients unable to provide written informed consent are excluded.&#xD;
&#xD;
          -  Patients with bleeding disorder are excluded from the study as a precaution.&#xD;
&#xD;
          -  Hospitalized patients/inpatients are excluded.&#xD;
&#xD;
          -  Application of nasal spray within 15 min prior to testing.&#xD;
&#xD;
          -  Participants with symptoms on the day of testing are excluded, if any of their&#xD;
             symptoms started more than 14 days prior to testing.&#xD;
&#xD;
          -  Asymptomatic participants are excluded, if they experienced any symptoms in the 14&#xD;
             days prior to testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Zickler, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Polzius, Dr</last_name>
    <phone>+49 451 882 4429</phone>
    <email>Rainer.Polzius@draeger.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Zickler, Dr</last_name>
      <phone>+49 30 450 514 002</phone>
      <email>daniel.zickler@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Klemens Budde, Dr</last_name>
      <phone>+49 30 450 514 002</phone>
      <email>klemens.budde@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antigen test</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

